Screening & TReatment fOr Perinatal WomeN With PTSD in Substance Use Care SettinGs in Arkansas (STRONG Moms) (STRONG Moms)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The primary objective is to evaluate the feasibility and acceptability of implementing a brief, telehealth-delivered behavioral intervention for PTSD among pregnant and postpartum individuals with a history of substance misuse. Secondary objectives include estimating the prevalence of probable PTSD in perinatal substance use treatment settings, assessing participant interest in receiving PTSD treatment while engaged in substance use care, and examining preliminary changes in PTSD and depressive symptoms following treatment.
The study consists of two sequential components. First, pregnant and postpartum individuals receiving services for problematic substance misuse in Arkansas will be screened for PTSD symptoms using the Primary Care PTSD Screen for DSM-5 (PC-PTSD-5). Screening will be conducted across multiple treatment and care settings, including inpatient and outpatient programs, to estimate the prevalence of probable PTSD and characterize willingness to participate in trauma-focused treatment during the perinatal period.
Second, individuals who meet eligibility criteria for PTSD treatment will participate in a mixed-methods, single-arm pre-post pilot evaluation of Written Exposure Therapy (WET), a brief evidence-based behavioral intervention for PTSD delivered via telehealth. Approximately 20 pregnant and postpartum participants with PTSD will receive the intervention. Feasibility will be assessed through measures such as recruitment, enrollment, retention, intervention completion, and assessment completion. Acceptability will be evaluated using participant-reported satisfaction and qualitative interviews exploring experiences with treatment delivery, barriers and facilitators to participation, and recommendations for implementation. Clinical assessments conducted before and after treatment will provide preliminary estimates of changes in PTSD symptoms and depressive symptoms.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mollee K. Steely Smith K Assistant Professor, PhD
- Phone Number: 501-526-8174
- Email: mksteelysmith@uams.edu
Study Contact Backup
- Name: Chelsey E Bull, PhD
- Email: cebull@uams.edu
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- University of Arkansas for Medical Sciences
-
Contact:
- Mollee K Steely Smith, PhD
- Phone Number: 501-526-8174
- Email: mksteelysmith@uams.edu
-
Contact:
- Chelsey E Bull, PhD
- Email: cebull@uams.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to write, understand, and speak English
- Able to give informed consent
- Currently pregnant or postpartum (≤ 6 months after childbirth)
- History of substance misuse
- Receiving services for substance-use related problems
- Have a history of traumatic event exposure
- Endorse clinically significant PTSD symptoms (score ≥ 3 on the Primary Care PTSD Screen for DSM-5; PC-PTSD-5)
Exclusion Criteria:
- Unwilling to provide consent
- No history of Criterion A trauma exposure or clinically significant PTSD symptoms
- No history of substance misuse or currently receiving services for a substance-use related problem
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Single Arm Intervention
All participants will receive Written Exposure Therapy (WET)
|
Written Exposure Therapy (WET) is a brief, evidence-based therapy for PTSD.
Clients receive 5 weekly sessions where they write about a traumatic experience in a safe, structured way for approximately 50 minutes followed by a brief check-in with their therapist.
This process helps individuals make sense of the event, reduce emotional distress, and decrease PTSD symptoms over time.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acceptability
Time Frame: From baseline to end of treatment at 5 weeks
|
Acceptability will be evaluated using the Client Satisfaction Questionnaire (CSQ-8), an 8-item participant-reported satisfaction measure rated on a 4-point Likert scale.
Total scores ranging from 8-32, with higher scores indicating greater satisfaction with the therapy.
|
From baseline to end of treatment at 5 weeks
|
|
Acceptability
Time Frame: From baseline to end of treatment at 5 weeks
|
Acceptability will also be evaluated using the Acceptability of Intervention (AIM), which is a 4-item self-reported questionnaire on a 5-point Likert scale assessing acceptability of the intervention.
Scores are summed and higher scores indicate greater acceptability.
|
From baseline to end of treatment at 5 weeks
|
|
Feasibility of Recruitment
Time Frame: From enrollment to end of treatment at 5 weeks
|
Feasibility of recruitment will be assessed by the number of individuals who initiated WET versus the total number of individuals enrolled in the study.
|
From enrollment to end of treatment at 5 weeks
|
|
Therapy Adherence
Time Frame: From enrollment to end of treatment at 5 weeks
|
Therapy adherence will be assessed by WET session attendance and completion.
We will measure therapy adherence by the number of individuals who complete ≥ 4 sessions versus the total number of individuals who received ≤ 3 sessions.
|
From enrollment to end of treatment at 5 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PTSD Symptoms
Time Frame: From enrollment to the end of treatment at 5 weeks
|
Changes in PTSD symptoms will be assessed using the PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report questionnaire on symptoms of PTSD.
Scores range from 0-80, with higher scores indicating a greater PTSD symptom severity.
|
From enrollment to the end of treatment at 5 weeks
|
|
Depression Symptoms
Time Frame: From enrollment to end of treatment at 5 weeks
|
Depression symptoms will be assessed using the Personal History Questionnaire (PHQ-9), a 9-item questionnaire used to assess depression symptoms over the past 2 weeks.
Total scores range from 0-27, with higher scores indicating greater severity of depression symptoms
|
From enrollment to end of treatment at 5 weeks
|
|
Substance Use Severity
Time Frame: From enrollment to end of treatment at 5 weeks
|
The DSM-5 Drug Use Disorder (DUD) and Alcohol Use Disorder (AUD) Symptom Checklist is a self-report measure to assess the presence of diagnostic criteria for drug use disorders.
This measure evaluates the 11 DSM-5 criteria for drug use disorders, including impaired control, social impairment, risky use, and pharmacologic indicators (tolerance/withdrawal).
Endorsement of a greater number of criteria indicates greater severity and can be categorized as mild, moderate, or severe.
|
From enrollment to end of treatment at 5 weeks
|
|
Pre/Postnatal Depression Symptoms
Time Frame: From enrollment to the end of treatment at 5 weeks
|
The Edinburgh Postnatal Depression Scale (EPDS), a 10-item self-report questionnaire to assess depressive symptoms experiences during the previous 7 days in pregnant and postpartum individuals, will also be used to assess perinatal postpartum depression.
Total scores range from 0-30, with higher scores indicating greater severity of depressive symptoms.
|
From enrollment to the end of treatment at 5 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mollee K Steely Smith, PhD, University of Arkansas
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 300210
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.